Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Relmada Therapeutics Stock Soars on Phase 2 Depression Study Results

Shares of Relmada Therapeutics have traded wildly today after it announced Phase 2 results for its anti-depressant drug dextromethadone. The firm's shares have traded 100–200% higher today and the stock was halted several times trading due to extreme price volatility. ...
Streetwise Reports | October 16, 2019 |

Intra-Cellular Therapies Shares Rise 200% on FDA Approval of Adult Schizophrenia Drug

Shares of Intra-Cellular Therapies opened greater than 100% higher today after the company reported that the FDA approved its antipsychotic CAPLYTA® (lumateperone) drug for the treatment of schizophrenia in adults. This morning a biopharmaceutical company foc...
Streetwise Reports | December 27, 2019 |

Revolutionizing Mental Health Treatment

(Click to play video.) Cybin Inc. ( NEO: CYBN , NYSE: CYBN , Forum ) is a Toronto-based life sciences company initially focused on psychedelic pharmaceutical therapies supporting research to advance psychedelic therapies centered on improving mental health and...
Featured Submission | August 13, 2021 |

Aging in the New World Order of Managed Markets

After over 40 years in the world of money and markets, I have arrived at the conclusion that aging can be a double-edged sword where the advantages created by many years of experience are many times odiously offset by innate biases that become ingrained over time. It came...
Streetwise Reports | March 22, 2019 |

Biopharma Co. Makes Major Headway Toward Clinical Trials for Treatment of Stroke

(CLICK IMAGE TO PLAY VIDEO) Finding an effective method of preventing the possibility of stroke is something that medical science has grappled with for decades. Now, a Vancouver-based clinical stage biopharmaceutical development company looks to be making significa...
Dave Jackson | June 16, 2021 |

Medcolcanna Prepares For Recurring Commercial Shipments

An Operational Update for 2021 as The Company Prepares for Recurring Shipments Medcolcanna Organics Inc. (NEO: MCCN), a leading Colombian and globally integrated cannabis company, is providing the following corporate update. Key highlights include: Capacity &...
Featured Submission | January 25, 2021 |

A Company on a Mission to Revolutionize Mental Healthcare. Here’s How.

When Stockhouse Editorial last caught up with Cybin Inc. ( NEO.CYBN , NYSE: CYBIN , Forum ) back in October, our audience learned about a leading biotechnology company focused on researching and progressing psychedelic therapeutics by utilizing proprietary drug discover...
Dave Jackson | January 31, 2022 |

A ‘Novel’ Investment In Psychedelic-Inspired Medicines

Stockhouse investors are keenly aware of the booming trend in the psychedelic healthcare space…in many ways the new Cannabis 2.0 over the last 12 – 24 months. Capital markets have taken to them en masse – a market now estimated to be in excess of USD$5 billion and expected ...
Dave Jackson | April 16, 2021 |

The Psychedelic Opportunity You Need to Know About

When Stockhouse Editorial last caught up with Toronto-based CYBIN Inc. ( N.CYBN , OTC: CYBN , Forum ) back in September 2020 , the psychedelic life sciences company was just going public…and to much fanfare. Cybin is a life sciences company that views psychedelic subst...
Dave Jackson | October 19, 2021 |

Buzz on the Bullboards: A Bigger Picture for Smaller Caps

(Image via Blackberry Ltd.) The business of war weighs on the minds of investors and companies today. It is not just that, but the push to re-emerge from the COVID-19 pandemic to supply chain issues, business has been adapting. Take BlackBerry Limited ( TSX: BB...
Stockhouse Editorial | March 23, 2022 |
1 2 3 4 5 6 7 8 9 10 ...